CN107488194B - Afatinib intermediate and preparation method thereof - Google Patents

Afatinib intermediate and preparation method thereof Download PDF

Info

Publication number
CN107488194B
CN107488194B CN201610405417.5A CN201610405417A CN107488194B CN 107488194 B CN107488194 B CN 107488194B CN 201610405417 A CN201610405417 A CN 201610405417A CN 107488194 B CN107488194 B CN 107488194B
Authority
CN
China
Prior art keywords
reaction
intermediate iii
organic solvent
tert
iii according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610405417.5A
Other languages
Chinese (zh)
Other versions
CN107488194A (en
Inventor
张贵民
赵绪亮
王秀娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Priority to CN201610405417.5A priority Critical patent/CN107488194B/en
Publication of CN107488194A publication Critical patent/CN107488194A/en
Application granted granted Critical
Publication of CN107488194B publication Critical patent/CN107488194B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The invention discloses a novel intermediate III of afatinib and a preparation method thereof, and the preparation method comprises the following steps: reducing the N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine to obtain N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV, and carrying out condensation reaction with diethylphosphonoacetic acid to obtain III. The method has high yield and high purity.

Description

Afatinib intermediate and preparation method thereof
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to an afatinib intermediate and a preparation method thereof.
Background
Afatinib maleate is a multi-target oral small molecule drug developed by bliringer-jehn, germany, and is an irreversible inhibitor of Epidermal Growth Factor Receptor (EGFR) and human epidermal receptor 2(HER2) tyrosine kinase. It is a second generation highly potent dual non-reversible tyrosine kinase inhibitor. The drug was approved by the U.S. FDA in 2013 on 7, 12 months. Under the trade name Gilotrif.
Afatinib maleate (I) with the chemical name 4- [ (3-chloro-4-fluorophenyl) amino ] -6- { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl ] amino } -7- ((S) -tetrahydrofuran-3-yloxy) -quinazoline dimaleate.
Figure GDA0003050295240000011
The preparation method of afatinib is reported in the primary chinese patent CN1867564B of the business of bouling invager: taking mother nucleus 4- [ (3-chloro-4-fluorophenyl) amino ] -6-nitro-7-fluoroquinazoline (V) as an initial raw material, and carrying out substitution reaction of halogen fluorine with S-3-hydroxy-tetrahydrofuran under the catalysis of a basic catalyst potassium tert-butoxide to generate 4- [ (3-chloro-4-fluorophenyl) amino ] -6-nitro-7- [ (S) - (tetrahydrofuran-3-yl) oxy ] quinazoline (1); the intermediate (1) is reduced by a nitro group at the 6-position to obtain a corresponding amino compound (2); the compound (2) and diethyl phosphoacetic acid are subjected to amidation reaction to obtain an intermediate (3), and the intermediate (3) and dimethylamino acetaldehyde diethyl acetal are subjected to Wittig-Horner-Emmons reaction to obtain afatinib (I).
Figure GDA0003050295240000021
According to other literature analysis, the starting material V is in butt joint with the chiral intermediate S-3-hydroxy-tetrahydrofuran, and then subsequent reaction is carried out to obtain the afatinib. The following defects are found in the prior literature through experiments:
the chiral intermediate S-3-hydroxy-tetrahydrofuran is expensive and has large loss in subsequent multi-step reactions;
the final product I produced by the Wittig-Horner-Emmons reaction carried out by the intermediate 3 has more impurities and is not easy to remove.
In order to solve the problems, it is necessary to find a more economical and practical route for synthesizing afatinib.
Disclosure of Invention
The invention aims to search a new preparation way and provide a preparation method of afatinib according to an atom economic synthesis concept of green chemistry.
The main technical scheme provided by the invention is as follows: an afatinib intermediate compound III is shown in the following structural formula:
Figure GDA0003050295240000031
a method for synthesizing an intermediate III comprises the following specific steps: reducing N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine V as an initial raw material to obtain N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV, carrying out condensation reaction with diethylphosphonoacetic acid to obtain III,
Figure GDA0003050295240000032
specifically, the method comprises the following steps:
1) reduction reaction: and adding the starting material V, a reducing agent, a catalyst and an organic solvent A into a reaction bottle for reduction reaction to obtain a compound IV.
2) Condensation reaction: and adding the compound IV, the diethylphosphonoacetic acid, the condensing agent and the organic solvent B into a reaction bottle for condensation reaction to obtain a compound III.
The organic solvent A, the organic solvent B and the organic solvent C are respectively and independently selected from one or more of aromatic hydrocarbons, aliphatic hydrocarbons, alicyclic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, amides, glycol derivatives, ester solvents and phenol; more preferably one or more of benzene, toluene, cyclohexane, methanol, ethanol, tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; further preferably, the organic solvent A is selected from one or more of tert-butyl alcohol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; most preferably t-butanol or acetone or a mixture of both.
In the reduction reaction, the catalyst is selected from 10% Pd/C, Zn, Fe and Fe (OH)3、FeO(OH)、FeCl3And Fe (OAc)2Is preferably FeCl3Or 10% Pd/C. Preferably, the amount of catalyst added is 0.03 to 0.05 times the amount of intermediate V.
In the reduction reaction, the reducing agent is selected from H2/Ni、LiAlH4、NaBH4One of hydrogen, ammonium formate, hydrazine hydrate and ammonium chloride, further preferably one of hydrogen, ammonium formate, hydrazine hydrate and ammonium chloride; more preferably hydrogen.
In the condensation reaction, the condensing agent is selected from one of 1, 3-Dicyclohexylcarbodiimide (DC), N '-Carbonyldiimidazole (CDI) and 1,1' -carbonylbis (1,2, 4-triazole) (CDT). Preferably, the amount of the condensing agent added is 0.3 to 1.5 times the amount of the intermediate IV.
In the condensation reaction, the organic solvent B is preferably one or more of tert-butyl alcohol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; most preferred is tetrahydrofuran or methyl tert-butyl ether.
Preferably, the reduction reaction step is to take the compound V, a catalyst and absolute ethyl alcohol and put the compound V and the catalyst into a single-mouth bottle, start electromagnetic stirring, replace air with nitrogen, replace nitrogen with hydrogen, keep the temperature and maintain the pressure for reaction, after the reaction is finished, remove the catalyst by decompression and suction filtration, and evaporate filtrate in a rotary manner to dryness to obtain an intermediate IV.
Preferably, the reduction reaction step comprises the steps of taking the compound V, a catalyst and absolute ethyl alcohol, placing the mixture into a single-mouth bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, carrying out heat preservation and pressure maintaining reaction for 4 hours, after the reaction is finished, carrying out reduced pressure suction filtration to remove the catalyst, and carrying out rotary evaporation on filtrate until the filtrate is dried to obtain an intermediate IV.
Preferably, the condensation reaction step is: and putting the diethylphosphonoacetic acid and tetrahydrofuran into a three-neck flask, starting stirring, slowly adding a condensing agent, carrying out heat preservation reaction, then adding the intermediate IV, continuing the heat preservation reaction, separating out a large amount of solid after the reaction is finished, adding methyl tert-butyl ether, stirring, carrying out suction filtration, and drying to obtain an intermediate III.
Further preferably, the condensation reaction step is: putting the diethylphosphonoacetic acid and the tetrahydrofuran into a three-neck flask, starting stirring, slowly adding the condensing agent, keeping the temperature at 40 ℃ for reaction for 1h, then adding the intermediate IV, keeping the temperature for reaction for 1h, separating out a large amount of solids after the reaction is finished, adding the methyl tert-butyl ether, stirring for 1h, carrying out suction filtration, and drying to obtain an intermediate III.
A method for synthesizing afatinib by using the intermediate III, the intermediate III and dimethylamino acetaldehyde diethyl acetal are subjected to Wittig-Horner-Emmons reaction to obtain a key intermediate II, and then the key intermediate II and (S) -3-hydroxytetrahydrofuran are subjected to substitution reaction to obtain a compound I,
Figure GDA0003050295240000051
specifically, the method comprises the following steps:
3) Wittig-Horner-Emmons reaction: adding the compound III, dimethylamino acetaldehyde diethyl acetal, concentrated hydrochloric acid, an organic solvent C and alkali A into a reaction bottle for reaction to obtain a compound II.
4) And (3) substitution reaction: and adding the compound II, (S) -3-hydroxytetrahydrofuran, alkali B and an organic solvent D into a reaction bottle for substitution reaction to obtain a compound I.
The base A in the wittig-Horner reaction is selected from organic bases or inorganic bases, preferably inorganic bases, and the inorganic bases are preferably 25% inorganic base aqueous solution. The inorganic base is selected from one of potassium hydroxide, sodium hydroxide, lithium hydroxide and cesium hydroxide, most preferably potassium hydroxide.
In the wittig-Horner reaction, the organic solvent C is preferably one or more of methanol, tert-butyl alcohol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; tetrahydrofuran is most preferred.
In the substitution reaction, the organic solvent D is selected from one or more of aromatic hydrocarbon, aliphatic hydrocarbon, alicyclic hydrocarbon, halogenated hydrocarbon, alcohol, ether, amide, glycol derivative, ester solvent and phenol; more preferably one or more selected from benzene, toluene, cyclohexane, methanol, ethanol, tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; most preferably tert-butanol.
In the substitution reaction, the base B is selected from one of sodium hydride, potassium hydride, calcium hydride and potassium tert-butoxide, and potassium tert-butoxide is more preferred.
Preferably, the Wittig-Horner-Emmons reaction step is first to deprotect the dimethylaminoethanol to yield dimethylaminoacetaldehyde. Weighing the intermediate III, placing the intermediate III in a three-neck flask, adding tetrahydrofuran solution of tetrahydrofuran and dimethylaminoacetaldehyde, stirring for dissolving, cooling to 0 ℃ in an ice bath, starting dropwise adding inorganic alkaline aqueous solution, controlling the temperature to be 0-5 ℃, naturally heating to room temperature after dropwise adding, pouring reaction liquid into water after reaction, stirring for crystallization, performing suction filtration, and drying to obtain an intermediate II.
Preferably, the substitution reaction is carried out, the intermediate II is weighed and placed in a three-necked bottle, tert-butyl alcohol is added, then (S) -3-hydroxytetrahydrofuran is added, potassium tert-butoxide is slowly added, the temperature is controlled to be not more than 50 ℃, the addition is completed, the stirring reaction is carried out for 1h, after the reaction is completed, the reaction liquid is poured into drinking water, 10% acetic acid water solution is used for regulating the pH value to be 6-7, and afatinib I is obtained through suction filtration and drying.
The final product of the route has less impurities and low cost, and is suitable for industrial production. The chiral intermediate S-3-hydroxy-tetrahydrofuran is used in the last step of the substitution reaction, so that the loss of expensive intermediates in multi-step reactions is reduced.
Detailed Description
In order to make the technical solutions of the present invention better understood by those skilled in the art, the following non-limiting examples are disclosed to further illustrate the present invention.
Example 1
The first step is as follows:
3.4g of compound V and 153mgFeCl were taken350mL of a mixed solution of tert-butyl alcohol and acetone (the volume ratio of tert-butyl alcohol to acetone is 3:4) is put into a single-mouth bottle, electromagnetic stirring is started, air is replaced by nitrogen for 3 times, nitrogen is replaced by hydrogen for 3 times, heat preservation and pressure maintaining are carried out for 4 hours, after the reaction is finished, a catalyst is removed by vacuum filtration, filtrate is evaporated to dryness in a rotary manner, and the intermediate IV is obtained by drying, wherein the yield is 99.6%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 50ml of tetrahydrofuran are put into a 250ml three-necked flask, stirring is started, 2.0g of CDI is slowly added, the temperature is kept at 40 ℃ for 1 hour of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 1 hour of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methyl tert-butyl ether is added, stirring is carried out for 1 hour, and then suction filtration and drying are carried out to obtain an intermediate III, wherein the yield is 98.1%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III into a 250ml three-neck flask, adding 50ml of tetrahydrofuran and 40ml of a tetrahydrofuran solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, starting to dropwise add 30g of 25% KOH aqueous solution, controlling the temperature to be 0-5 ℃, after dropwise adding, naturally heating to room temperature, pouring reaction liquid into 300ml of water after the reaction is finished, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 97.4%, and the purity is 99.8%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of tert-butyl alcohol, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding potassium tert-butoxide, controlling the temperature to be not more than 50 ℃, stirring for reaction for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to 6.5 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain the afatinib I, wherein the yield is 89%, the purity is 99.6%, and the single impurity content is less than 0.1%.
Example 2
The first step is as follows:
3.4g of the compound V, 102mg of 10% Pd/C and 50mL of methyl tert-butyl ether are put into a single-mouth bottle, electromagnetic stirring is started, air is replaced by nitrogen for 3 times, nitrogen is replaced by hydrogen for 3 times, heat preservation and pressure maintaining are carried out for 4 hours, after the reaction is finished, the catalyst is removed by vacuum filtration, filtrate is evaporated to dryness in a rotary manner, and the yield is 99.1%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 50ml of methyl tert-butyl ether are put into a 250ml three-necked flask, stirring is started, 4.5g of CDI is slowly added, the temperature is kept at 40 ℃ for 1h of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 1h of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methyl tert-butyl ether is added, stirring is carried out for 1h, suction filtration is carried out, and drying is carried out to obtain an intermediate III, wherein the yield is 97.1%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of DMF and 40ml of DMF solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 30g of 25% NaOH aqueous solution, controlling the temperature to be 0-5 ℃, after dropwise addition, naturally heating to room temperature, pouring reaction liquid into 300ml of water after reaction, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 96.2% and the purity is 99.6%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of acetone, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding sodium hydride, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to 7 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 87%, the purity is 99.6%, and the single impurity content is less than 0.1%.
Example 3
The first step is as follows:
collecting 3.4g of Compound V, 170mgFe (OH)3100mL of acetone is put into a single-mouth bottle, electromagnetic stirring is started, and nitrogen is put inAnd (3) exchanging air for 3 times, exchanging nitrogen for 3 times by hydrogen, carrying out heat preservation and pressure maintaining reaction for 6 hours, after the reaction is finished, carrying out reduced pressure suction filtration to remove the catalyst, carrying out rotary evaporation on the filtrate until the filtrate is dried, and drying to obtain an intermediate IV with the yield of 99.0%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 80ml of methanol are put into a 250ml three-necked flask, stirring is started, 0.9g of DCC is slowly added, the temperature is kept at 40 ℃ for 1h of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 1h of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methanol is added, stirring is carried out for 1h, suction filtration is carried out, and drying is carried out to obtain an intermediate III, wherein the yield is 96.2%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of ethanol and 40ml of ethanol solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 30g of 25% LiOH aqueous solution, controlling the temperature to be 0-5 ℃, after dropwise addition, naturally heating to room temperature, after the reaction is finished, pouring the reaction liquid into 300ml of water, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 95.1% and the purity is 99.5%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of ethyl acetate, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding potassium hydride, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to be 6 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 87%, the purity is 99.5%, and the single impurity content is less than 0.1%.
Comparative example 1
The first step is as follows:
taking 3.4g of a compound V, 80mg of a catalyst, 10% palladium-carbon and 100mL of methanol, putting the mixture into a single-opening bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, carrying out heat preservation and pressure maintaining reaction for 2 hours, after the reaction is finished, carrying out reduced pressure suction filtration to remove the catalyst, and carrying out rotary evaporation on filtrate until the filtrate is dried to obtain an intermediate IV, wherein the yield is 95.2%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 80ml of methanol are put into a 250ml three-necked bottle, stirring is started, 5.2g of condensing agent DCC is slowly added, the temperature is kept at 48 ℃ for 2 hours of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 2 hours of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methanol is added, stirring is carried out for 2 hours, and then suction filtration and drying are carried out to obtain intermediate III, wherein the yield is 88.6%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of ethanol and 40ml of ethanol solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 25g of 20% LiOH aqueous solution, controlling the temperature to be 10-15 ℃, after dropwise addition, naturally heating to room temperature, after the reaction is finished, pouring the reaction liquid into 300ml of water, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 81.3%, and the purity is 98.2%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of heptane, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding lithium hydroxide, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to be 6.5 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 78% and the purity is 95.2%.
Comparative example 2
The first step is as follows:
taking 3.4g of compound V and 200mg of catalyst PdCl2Putting DTBPF and 100mL of methanol into a single-mouth bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, preserving heat and maintaining pressure for reaction for 3 hours, reducing pressure and filtering to remove the catalyst after the reaction is finished, and rotatably steaming the filtrate to be dry to obtain an intermediate IV with the yield of 89.2%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 80ml of methanol are put into a 250ml three-necked bottle, stirring is started, 2.0g of condensing agent DMC is slowly added, the temperature is kept at 40 ℃ for 2 hours of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 2 hours of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methanol is added, stirring is carried out for 2 hours, suction filtration is carried out, and drying is carried out to obtain an intermediate III, wherein the yield is 78.9%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of ethanol and 40ml of ethanol solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 25g of 35% LiOH aqueous solution, controlling the temperature to be 10-15 ℃, after finishing dripping, naturally heating to room temperature, after the reaction is finished, pouring the reaction liquid into 300ml of water, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 72.1%, and the purity is 95.1%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of n-hexane, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding sodium hydroxide, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 100ml of drinking water after the reaction is finished, adjusting the pH value to be 6.5 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 74% and the purity is 94.0%.

Claims (14)

1. An afatinib intermediate III is shown in the following structural formula:
Figure FDA0002819230600000011
2. a preparation method of an afatinib intermediate III is characterized by comprising the following steps: reducing N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine V as an initial raw material to obtain N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV, carrying out condensation reaction with diethylphosphonoacetic acid to obtain III,
Figure FDA0002819230600000012
3. the process for preparing afatinib intermediate iii according to claim 2, characterized in that: the method specifically comprises the following steps:
1) reduction reaction: adding the starting material V, a reducing agent, a catalyst and an organic solvent A into a reaction bottle for reduction reaction to obtain a compound IV;
2) condensation reaction: and adding the compound IV, diethyl phosphoacetic acid, a condensing agent and an organic solvent B into a reaction bottle for condensation reaction to obtain a compound III.
4. The method for preparing afatinib intermediate iii according to claim 3, wherein the organic solvent a and the organic solvent B are each independently selected from one or more of aromatic hydrocarbons, aliphatic hydrocarbons, alicyclic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, amides, glycol derivatives, ester solvents, and phenols.
5. The method for preparing afatinib intermediate iii according to claim 4, wherein the organic solvent a and the organic solvent B are each independently selected from one or more of benzene, toluene, cyclohexane, methanol, ethanol, tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate, or DMF.
6. The method for preparing afatinib intermediate iii according to claim 3, wherein the organic solvent a is selected from one or more of tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF.
7. The preparation method of afatinib intermediate iii according to claim 6, wherein the organic solvent a is tert-butanol or acetone or a mixed solution of the tert-butanol and the acetone.
8. The method for preparing afatinib intermediate iii according to claim 3, wherein the organic solvent B is selected from one or more of tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF.
9. The method for preparing afatinib intermediate iii according to claim 8, wherein the organic solvent B is tetrahydrofuran or methyl tert-butyl ether.
10. The process of claim 3, wherein the catalyst in the reduction reaction is selected from the group consisting of 10% Pd/C, Zn, Fe (OH)3、FeO(OH)、FeCl3Or Fe (OAc)2。
11. The method for preparing afatinib intermediate iii according to claim 3, wherein the catalyst in the reduction reaction is FeCl3Or 10% Pd/C.
12. The process for preparing afatinib intermediate iii according to claim 3, wherein the reducing agent in the reduction reaction is selected from H2/Ni、LiAlH4、NaBH4Hydrogen, ammonium formate, hydrazine hydrate or ammonium chloride.
13. The method for preparing afatinib intermediate iii according to claim 12, wherein the reducing agent in the reduction reaction is selected from hydrogen gas, ammonium formate, hydrazine hydrate or ammonium chloride.
14. The method of claim 13, wherein the reducing agent in the reduction reaction is hydrogen.
CN201610405417.5A 2016-06-10 2016-06-10 Afatinib intermediate and preparation method thereof Active CN107488194B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610405417.5A CN107488194B (en) 2016-06-10 2016-06-10 Afatinib intermediate and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610405417.5A CN107488194B (en) 2016-06-10 2016-06-10 Afatinib intermediate and preparation method thereof

Publications (2)

Publication Number Publication Date
CN107488194A CN107488194A (en) 2017-12-19
CN107488194B true CN107488194B (en) 2021-07-30

Family

ID=60642687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610405417.5A Active CN107488194B (en) 2016-06-10 2016-06-10 Afatinib intermediate and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107488194B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635498A1 (en) * 1993-07-19 1995-01-25 Zeneca Limited Quinazoline derivatives and their use as anti-cancer agents
CN1218456A (en) * 1996-04-12 1999-06-02 沃尼尔·朗伯公司 Irreversible inhibitors of tyrosine kinases
CN1867564A (en) * 2003-10-17 2006-11-22 贝林格尔·英格海姆国际有限公司 Process for preparing amino crotonyl compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635498A1 (en) * 1993-07-19 1995-01-25 Zeneca Limited Quinazoline derivatives and their use as anti-cancer agents
US5475001A (en) * 1993-07-19 1995-12-12 Zeneca Limited Quinazoline derivatives
CN1218456A (en) * 1996-04-12 1999-06-02 沃尼尔·朗伯公司 Irreversible inhibitors of tyrosine kinases
CN1867564A (en) * 2003-10-17 2006-11-22 贝林格尔·英格海姆国际有限公司 Process for preparing amino crotonyl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Process for the preparation of afatinib;Disclosed Anonymously;《IP.com Journal》;20150930;第15卷(第10A期);第1-3页 *

Also Published As

Publication number Publication date
CN107488194A (en) 2017-12-19

Similar Documents

Publication Publication Date Title
CN111807973B (en) Preparation method of vilanterol and salt thereof
CN107488194B (en) Afatinib intermediate and preparation method thereof
CN107488153B (en) Afatinib intermediate compound
CN107488152B (en) Afatinib intermediate and synthetic method thereof
CN107056681B (en) A kind of support method replaces the preparation method of cloth intermediate
CN107488171B (en) Preparation method of afatinib
WO2015111085A2 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN112028896A (en) Novel crystal form of acatinib and preparation method thereof
CN107488172B (en) Preparation method of afatinib
CN112457304B (en) Preparation method of nifuratel
CN114957134A (en) Method for preparing azoxystrobin and intermediate thereof
CN111100042B (en) Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN110642721B (en) Preparation method of selegiline hydrochloride
CN110668952B (en) Preparation method of benzphetamine hydrochloride
CN113087622A (en) Preparation method of eptazocine intermediate
CN112920233A (en) Synthetic method of emamectin benzoate with improved processability
EP3650444A1 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
CN110698381A (en) Method for synthesizing N- (benzyloxycarbonyl) succinimide by one-pot two-phase method
US10611721B2 (en) Method for preparing levobunolol hydrochloride
CN116947691B (en) Preparation method of fluvoxamine maleate
CN108997248B (en) Crystal form B of ondarot hydrochloride and preparation method thereof
CN116836069B (en) Preparation method of levosalbutamol hydrochloride
CN113372314B (en) High-purity furandiene crystal and preparation method thereof
CN110668951B (en) Synthesis process of selegiline hydrochloride
CN111978188B (en) Preparation method of mexiletine hydrochloride impurity C

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: The invention relates to an afatinib intermediate and a preparation method thereof

Effective date of registration: 20211224

Granted publication date: 20210730

Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch

Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd.

Registration number: Y2021980016193

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20221028

Granted publication date: 20210730

Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch

Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd.

Registration number: Y2021980016193

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: An intermediate of alfatinib and its preparation method

Effective date of registration: 20221103

Granted publication date: 20210730

Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch

Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd.

Registration number: Y2022980020531

PE01 Entry into force of the registration of the contract for pledge of patent right